公开(公告)号：US20220202814A1

公开(公告)日：2022-06-30

申请号：US17472130

申请日：2021-09-10

申请人： MingSight Pharmaceuticals, Inc.

发明人： Michael NIESMAN ,  Kai ZHANG

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61P35/02 ,  A61P35/00

摘要： Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein are compositions and methods for the treatment of Ewing's Sarcoma. Said compositions comprise isoform selective pyrrolo-pyrazole PKC inhibitors.

公开(公告)号：US20170196865A1

公开(公告)日：2017-07-13

申请号：US15313031

申请日：2015-05-22

申请人： MingSight Pharmaceuticals, Inc.

发明人： Michael NIESMAN ,  Kai ZHANG

IPC分类号： A61K31/506

CPC分类号： A61K31/506 ,  A61K31/496 ,  A61K31/53 ,  C07D487/04

摘要： Provided herein are compositions and methods for the treatment of autoimmune diseases, including lupus, uveitis and encephalitis. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole PKC inhibitors.

公开(公告)号：US20220000870A1

公开(公告)日：2022-01-06

申请号：US17469715

申请日：2021-09-08

申请人： MingSight Pharmaceuticals, Inc.

发明人： Michael NIESMAN ,  Kai ZHANG

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02

摘要： Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein are compositions and methods for the treatment of Ewing's Sarcoma. Said compositions comprise isoform selective pyrrolo-pyrazole PKC inhibitors.

公开(公告)号：US20210069194A1

公开(公告)日：2021-03-11

申请号：US16962806

申请日：2019-01-17

申请人： MingSight Pharmaceuticals, Inc.

发明人： Michael NIESMAN ,  Kai ZHANG

IPC分类号： A61K31/519 ,  A61K35/17

摘要： Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein are compositions and methods for the treatment of Ewing's sarcoma. Said methods comprise the administration of isoform selective pyrrolo-pyrazole PKC inhibitors and CAR-T therapy.

公开(公告)号：US20220202815A1

公开(公告)日：2022-06-30

申请号：US17472544

申请日：2021-09-10

申请人： MingSight Pharmaceuticals, Inc.

发明人： Michael NIESMAN ,  Kai ZHANG

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61P35/02 ,  A61P35/00

摘要： Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein are compositions and methods for the treatment of Ewing's Sarcoma. Said compositions comprise isoform selective pyrrolo-pyrazole PKC inhibitors.

公开(公告)号：US20230099852A1

公开(公告)日：2023-03-30

申请号：US17976710

申请日：2022-10-28

申请人： MINGSIGHT PHARMACEUTICALS, INC.

发明人： Michael NIESMAN ,  Kai ZHANG

IPC分类号： A61K31/506 ,  A61P19/04 ,  A61P27/02 ,  A61P25/00 ,  A61P37/06 ,  A61P19/02 ,  C07D487/04 ,  A61P17/06 ,  A61P1/00

摘要： Provided herein are compositions and methods for the treatment of autoimmune and alloimmune diseases and conditions, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis), optic neuritis, Neuromyelitis Optica, Sjögren's syndrome, psoriasis, systemic scleroderma, Ankylosing Spondylitis, autoimmune hepatitis, Graft vs host disease (GvHD), and organ transplant rejection. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole PKC inhibitors.

公开(公告)号：US20230028918A1

公开(公告)日：2023-01-26

申请号：US17782091

申请日：2020-12-04

申请人： MINGSIGHT PHARMACEUTICALS, INC.

发明人： Michael NIESMAN ,  Kai ZHANG ,  Kay OLMSTEAD

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61K45/06

摘要： The present invention relates, in some respects, to methods of using, and compositions comprising, a protein kinase inhibitor and pharmaceutically acceptable salts, solvates, and hydrates thereof. In some embodiments, the present invention relates to modified or extended release pharmaceutical formulations in the form of particles which, in some embodiments, are used in a tablet, capsule, or particulate form, for slowly releasing the protein kinase inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, over periods of time from at least 8 to 12 hours. The compositions of the present invention are useful in the treatment of PKCβ related disorders.

公开(公告)号：US20210401837A1

公开(公告)日：2021-12-30

申请号：US17469551

申请日：2021-09-08

申请人： MingSight Pharmaceuticals, Inc.

发明人： Michael NIESMAN ,  Kai ZHANG

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02

摘要： Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein are compositions and methods for the treatment of Ewing's Sarcoma. Said compositions comprise isoform selective pyrrolo-pyrazole PKC inhibitors.

公开(公告)号：US20180318300A1

公开(公告)日：2018-11-08

申请号：US15774996

申请日：2016-11-14

申请人： MingSight Pharmaceuticals, Inc.

发明人： Michael NIESMAN ,  Kai ZHANG

IPC分类号： A61K31/506 ,  A61P19/02 ,  A61P17/06 ,  A61P19/04 ,  A61P1/00 ,  A61P25/00 ,  A61P27/02 ,  A61P37/06

CPC分类号： A61K31/506 ,  A61P1/00 ,  A61P17/06 ,  A61P19/02 ,  A61P19/04 ,  A61P25/00 ,  A61P27/02 ,  A61P37/06 ,  C07D487/04

摘要： Provided herein are compositions and methods for the treatment of autoimmune and alloimmune diseases and conditions, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis), optic neuritis, Neuromyelitis Optica, Sjögren's syndrome, psoriasis, systemic scleroderma, Ankylosing Spondylitis, autoimmune hepatitis, Graft vs host disease (GvHD), and organ transplant rejection. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole PKC inhibitors.

公开(公告)号：US20180098988A1

公开(公告)日：2018-04-12

申请号：US15788678

申请日：2017-10-19

申请人： MingSight Pharmaceuticals, Inc.

发明人： Michael NIESMAN ,  Kai ZHANG

IPC分类号： A61K31/506

CPC分类号： A61K31/506 ,  A61K31/496 ,  A61K31/53 ,  C07D487/04

摘要： Provided herein are compositions and methods for the treatment of autoimmune diseases, including lupus, uveitis and encephalitis. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole PKC inhibitors.